These results suggest that conjugation of CIRP to large tumor antigens should be preferred, to enhance the possibility of including CD4 epitopes that provide T-cell help to other immune subsets, and to include several CD8 and CD4 epitopes presentable by different HLA alleles, broadening thus the proportion of individuals in a heterogeneous population. The gene discussed is CD8A; the disease is neoplasm.